Pharmicell Statistics

Total Valuation

Pharmicell has a market cap or net worth of KRW 604.24 billion.

Market Cap	604.24B
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	Dec 27, 2024

Share Statistics

Pharmicell has 60.00 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	60.00M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+1.98%
Owned by Insiders (%)	9.26%
Owned by Institutions (%)	9.14%
Float	54.26M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	25.23
PB Ratio	7.17
P/TBV Ratio	12.20
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.34, with a Debt / Equity ratio of 0.14.

Current Ratio	1.34
Quick Ratio	1.05
Debt / Equity	0.14
Debt / EBITDA	n/a
Debt / FCF	-1.50
Interest Coverage	-7.48

Financial Efficiency

Return on equity (ROE) is -29.25% and return on invested capital (ROIC) is -5.33%.

Return on Equity (ROE)	-29.25%
Return on Assets (ROA)	-4.98%
Return on Invested Capital (ROIC)	-5.33%
Return on Capital Employed (ROCE)	-10.54%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.21
Inventory Turnover	5.05

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +80.72% in the last 52 weeks. The beta is 0.29, so Pharmicell's price volatility has been lower than the market average.

Beta (5Y)	0.29
52-Week Price Change	+80.72%
50-Day Moving Average	10,484.20
200-Day Moving Average	7,200.95
Relative Strength Index (RSI)	51.69
Average Volume (20 Days)	793,451

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharmicell had revenue of KRW 23.94 billion and -26.78 billion in losses. Loss per share was -613.75.

Revenue	23.94B
Gross Profit	5.45B
Operating Income	-9.29B
Pretax Income	-26.75B
Net Income	-26.78B
EBITDA	-6.18B
EBIT	-9.29B
Loss Per Share	-613.75

Full Income Statement

Balance Sheet

The company has 9.44 billion in cash and 11.74 billion in debt, giving a net cash position of -2.30 billion or -38.34 per share.

Cash & Cash Equivalents	9.44B
Total Debt	11.74B
Net Cash	-2.30B
Net Cash Per Share	-38.34
Equity (Book Value)	84.27B
Book Value Per Share	1,867.90
Working Capital	4.72B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -7.55 billion and capital expenditures -272.69 million, giving a free cash flow of -7.82 billion.

Operating Cash Flow	-7.55B
Capital Expenditures	-272.69M
Free Cash Flow	-7.82B
FCF Per Share	-130.32

Full Cash Flow Statement

Margins

Gross margin is 22.74%, with operating and profit margins of -38.80% and -111.85%.

Gross Margin	22.74%
Operating Margin	-38.80%
Pretax Margin	-111.71%
Profit Margin	-111.85%
EBITDA Margin	-25.83%
EBIT Margin	-38.80%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 20.00, which amounts to a dividend yield of 0.21%.

Dividend Per Share	20.00
Dividend Yield	0.21%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	n/a
Buyback Yield	-7.56%
Shareholder Yield	-7.35%
Earnings Yield	-4.43%
FCF Yield	-1.29%

Dividend Details

Stock Splits

The last stock split was on December 1, 2011. It was a forward split with a ratio of 10.

Last Split Date	Dec 1, 2011
Split Type	Forward
Split Ratio	10

Scores

Pharmicell has an Altman Z-Score of 4.6.

Altman Z-Score	4.6
Piotroski F-Score	n/a